BACKGROUND AND AIMS: Methamphetamine use is increasingly prevalent and associated with HIV transmission. Early-phase human studies suggested naltrexone reduced amphetamine use among dependent individuals. We tested if extended-release naltrexone (XRNTX) reduces methamphetamine use and associated sexual risk behaviors among high-risk methamphetamine-dependent men who have sex with men (MSM). DESIGN: Double-blind, placebo-controlled, randomized trial of XRTNX versus placebo over 12 weeks from 2012 to 2015. SETTING: San Francisco Department of Public Health, California, USA. PARTICIPANTS: One hundred community-recruited, sexually-active, actively-using methamphetamine-dependent MSM. Mean age was 43.2 years; 96% were male, 3% transfemale, and 1% transmale; 55.0% were white, 19.0% African American, and 18.0% Latino. INTERVENTIONS:XRNTX 380 mg (n = 50) or matched placebo (n = 50) administered by gluteal injection at 4-week intervals. MEASUREMENTS: Regression estimated average level and change in level of positive urines during the period 2-12 weeks (primary outcomes) and sexual risk behaviors (secondary outcome). FINDINGS: Ninety per cent of visits were completed. By intent-to-treat, participants assigned to XRNTX had similar differences during 2-12 weeks in methamphetamine-positive urines as participants assigned to placebo [incidence rate ratio (IRR) = 0.95, 95% confidence interval (CI) = 0.76-1.20; Bayes factor < 0.3]. Observed urine positivity declined from 78 to 70% in the XRNTX arm and 74 to 64% in the placebo arm. Adherence to injections was 96.7% in the XRNTX arm and 91.3% in the placebo arm. Sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug and no differences in frequency of adverse events by treatment arm. CONCLUSIONS: Notwithstanding very high medication adherence for this study, extended-release naltrexone does not appear to reduce methamphetamine use or sexual risk behaviors among methamphetamine-dependent men who have sex with men compared with placebo.
RCT Entities:
BACKGROUND AND AIMS: Methamphetamine use is increasingly prevalent and associated with HIV transmission. Early-phase human studies suggested naltrexone reduced amphetamine use among dependent individuals. We tested if extended-release naltrexone (XRNTX) reduces methamphetamine use and associated sexual risk behaviors among high-risk methamphetamine-dependent men who have sex with men (MSM). DESIGN: Double-blind, placebo-controlled, randomized trial of XRTNX versus placebo over 12 weeks from 2012 to 2015. SETTING: San Francisco Department of Public Health, California, USA. PARTICIPANTS: One hundred community-recruited, sexually-active, actively-using methamphetamine-dependent MSM. Mean age was 43.2 years; 96% were male, 3% transfemale, and 1% transmale; 55.0% were white, 19.0% African American, and 18.0% Latino. INTERVENTIONS:XRNTX 380 mg (n = 50) or matched placebo (n = 50) administered by gluteal injection at 4-week intervals. MEASUREMENTS: Regression estimated average level and change in level of positive urines during the period 2-12 weeks (primary outcomes) and sexual risk behaviors (secondary outcome). FINDINGS: Ninety per cent of visits were completed. By intent-to-treat, participants assigned to XRNTX had similar differences during 2-12 weeks in methamphetamine-positive urines as participants assigned to placebo [incidence rate ratio (IRR) = 0.95, 95% confidence interval (CI) = 0.76-1.20; Bayes factor < 0.3]. Observed urine positivity declined from 78 to 70% in the XRNTX arm and 74 to 64% in the placebo arm. Adherence to injections was 96.7% in the XRNTX arm and 91.3% in the placebo arm. Sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug and no differences in frequency of adverse events by treatment arm. CONCLUSIONS: Notwithstanding very high medication adherence for this study, extended-release naltrexone does not appear to reduce methamphetamine use or sexual risk behaviors among methamphetamine-dependent men who have sex with men compared with placebo.
Authors: Adam W Carrico; Walter Gόmez; Jennifer Jain; Steven Shoptaw; Michael V Discepola; David Olem; Justin Lagana-Jackson; Rick Andrews; Torsten B Neilands; Samantha E Dilworth; Jennifer L Evans; William J Woods; Judith T Moskowitz Journal: Drug Alcohol Depend Date: 2018-09-05 Impact factor: 4.492
Authors: Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis Journal: Drug Alcohol Depend Date: 2018-09-21 Impact factor: 4.492
Authors: Raminta Daniulaityte; Sydney M Silverstein; Timothy N Crawford; Silvia S Martins; William Zule; Angela J Zaragoza; Robert G Carlson Journal: Subst Use Misuse Date: 2020-05-22 Impact factor: 2.164
Authors: Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray Journal: Am J Drug Alcohol Abuse Date: 2020-04-28 Impact factor: 3.829
Authors: Justin R Yates; Hunter L Campbell; Lauren L Hawley; Matthew J Horchar; Joy L Kappesser; Makayla R Wright Journal: Drug Alcohol Depend Date: 2021-05-26 Impact factor: 4.852
Authors: Milky Kohno; Angelica M Morales; Laura E Dennis; Holly McCready; William F Hoffman; P Todd Korthuis Journal: Front Psychiatry Date: 2019-09-03 Impact factor: 4.157
Authors: Jeremy D Kidd; Margaret M Paschen-Wolff; Amy A Mericle; Billy A Caceres; Laurie A Drabble; Tonda L Hughes Journal: J Subst Abuse Treat Date: 2021-06-16